Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82926 | 0.80 | CYP4F2 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL82141 | 0.79 | CTSK (0.33) | — | |
| SCHEMBL2312894 | 0.77 | MAPK1 (0.34) | CYP4F2CYP4A11DGAT1 | |
| Formaldehyde SCHEMBL27542028 | 0.74 | MAPK1 (0.33) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL4214456 | 0.71 | DGAT1 (0.36) | DGAT1 | |
| Formic Acid SCHEMBL27651219 | 0.71 | MAPK1 (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL10004931 | 0.70 | MAPK1 (0.35) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL1306106 | 0.70 | CYP4F2 (0.35) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL10835890 | 0.70 | USP2 (0.33) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL4499031 | 0.70 | MAPK1 (0.33) | CYP4F2CYP4A11DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211910-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | AAAS, NPEPPS, TEAD4 | CYP4F2 2323/4885CYP4A11 3096/4885DGAT1 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.